scholarly journals A prospective multicenter observational study of cell‐mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients

2019 ◽  
Vol 19 (9) ◽  
pp. 2505-2516 ◽  
Author(s):  
Deepali Kumar ◽  
Peter Chin‐Hong ◽  
Liise Kayler ◽  
David Wojciechowski ◽  
Ajit P. Limaye ◽  
...  
Keyword(s):  
Observational Study ◽  
Kidney Transplant ◽  
Cytomegalovirus Infection ◽  
Cell Mediated Immunity ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Multicenter Observational Study ◽  
Prospective Multicenter Observational Study

Risk Factors for Late-Onset Cytomegalovirus Infection or Disease in Kidney Transplant Recipients

2014 ◽  
Vol 97 (5) ◽  
pp. 569-575 ◽  
Author(s):  
Alainna J. Jamal ◽  
Shahid Husain ◽  
Yanhong Li ◽  
Olusegun Famure ◽  
S. Joseph Kim
Keyword(s):  
Risk Factors ◽  
Kidney Transplant ◽  
Cytomegalovirus Infection ◽  
Late Onset ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered from COVID-19.

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Mario Fernández-Ruiz ◽  
Beatriz Olea ◽  
Estela Giménez ◽  
Rocío Laguna-Goya ◽  
Hernando Trujillo ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Cell Mediated Immunity ◽  
Specific Cell ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Klemens Budde ◽  
Thomas Rath ◽  
Volker Kliem
Keyword(s):  
Adverse Events ◽  
Observational Study ◽  
Kidney Transplant ◽  
Prospective Observational Study ◽  
Erythropoietin Receptor ◽  
Study Entry ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Receptor Activator ◽  
Continuous Erythropoietin Receptor Activator

In a multicenter, prospective, observational study of 279 kidney transplant recipients with anemia, the efficacy and safety of once-monthly continuous erythropoietin receptor activator (C.E.R.A.) were assessed to a maximum of 15 months. The main efficacy variable was the proportion of patients achieving a hemoglobin level of 11-12 g/dL at each of visits between months 7 and 9. At study entry, 224 patients (80.3%) were receiving erythropoiesis stimulating agent (ESA) therapy including darbepoetin alfa (98), epoetin beta (61), and C.E.R.A. (45). The mean (SD) time between C.E.R.A. applications was 34.0 (11.9) days. Among 193 patients for whom efficacy data were available, mean (SD) hemoglobin was 11.1 (0.99) g/dL at study entry, 11.5 (1.1) g/dL at month 7, 11.6 (1.3) g/dL at month 9, and 11.4 (1.1) g/dL at month 15. During months 7–9, 20.7% of patients had all hemoglobin values within the range 11-12 g/dL and 64.8% were within 10–13 g/dL. Seven patients (2.5%) discontinued C.E.R.A. due to adverse events or serious adverse events. In this observational trial under real-life conditions, once-monthly C.E.R.A. therapy achieved stable hemoglobin levels in stable kidney transplant recipients with good tolerability, and with no requirement for any dose change in 43% of patients.

Sign in / Sign up

Export Citation Format

Share Document